PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Brolucizumab→

Brolucizumab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1531589-13-5
Molecular formula
C1164H1768N310O372S8
Molecular weight
26312.88 g/mol
Drug class
Humanised monoclonal antibody fragment (scFv)vascular endothelial growth factor A (VEGF-A) inhibitor
Mechanism of action
Binds VEGF-A isoforms and prevents their interaction with VEGF receptors, reducing endothelial-cell proliferation, neovascularisation and vascular permeability in the retina.
Indications / reported uses
  • Treatment of neovascular (wet) age-related macular degeneration (nAMD) in adults
  • Treatment of diabetic macular oedema (DME) in adults where authorised by the relevant product label

Sources: US FDA prescribing information — BEOVU · EMA EPAR — Beovu · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Brolucizumab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Brolucizumab Permitted Daily Exposure (PDE) report (the Brolucizumab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Brolucizumab Occupational Exposure Limit (OEL) report (the Brolucizumab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.